BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12

• Press Releases

  Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  January 12, 2026

   · 

  3 min read
• Press Releases

  RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

  January 12, 2026

   · 

  36 min read
• Press Releases

  Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

  January 12, 2026

   · 

  19 min read
• Press Releases

  Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

  January 12, 2026

   · 

  12 min read
• Press Releases

  Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

  January 12, 2026

   · 

  10 min read
• Press Releases

  Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

  January 12, 2026

   · 

  10 min read
• Press Releases

  Kinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to Advance Novel, Inhaled Therapeutic Candidate for Respiratory Diseases

  January 12, 2026

   · 

  4 min read
• Press Releases

  RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer

  January 12, 2026

   · 

  7 min read
• Press Releases

  Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

  January 12, 2026

   · 

  19 min read
• Press Releases

  Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

  January 12, 2026

   · 

  10 min read